Physician profile
Rohit Maini
NPI 1497199624
$6,125.66
in general payments reported to CMS, 2019-2025
25 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $241 · 2021: $347 · 2022: $3,244 · 2023: $121 · 2024: $680 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,364.42 | 2019-2025 | Coroflow, Optis |
| Abiomed | $487.90 | 2019-2025 | Impella |
| Medtronic, INC. | $451.22 | 2024-2025 | Symplicity G3, Hawkone |
| Medtronic Vascular, INC. | $305.24 | 2019-2020 | |
| Philips North America LLC | $269.48 | 2019 | |
| Penumbra, INC. | $264.07 | 2021-2024 | Penumbra System, Indigo System |
| Biotronik INC. | $243.07 | 2019 | |
| Boston Scientific Corporation | $121.08 | 2019 | |
| Cook Medical LLC | $118.55 | 2019 | |
| Novo Nordisk INC | $70.60 | 2024 | Ozempic, Rybelsus |
| Shockwave Medical, INC | $57.28 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Impulse Dynamics (USA) INC. | $48.88 | 2023 | Optimizer |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.47 | 2024 | Xarelto |
| Inari Medical, INC. | $39.36 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.14 | 2023 | Jardiance |
| Cardiovascular Systems INC. | $26.02 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $23.98 | 2019 | |
| Merck Sharp & Dohme LLC | $21.97 | 2022 | |
| Cordis US Corp. | $17.76 | 2025 | Mynx Control Venous |
| E.R. Squibb & Sons, L.L.C. | $16.40 | 2025 | Camzyos |
| Becton, Dickinson and Company | $15.51 | 2024 | Rotarexs 6 F X 135 Cm |
| Sandoz INC. | $14.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2023 | Farxiga |
| United Therapeutics Corporation | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Maini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.